Key result
ACEi or ARB therapy is linked to ~44% lower all-cause mortality in moderate-to-severe aortic regurgitation.
Why the study?
Long-term studies evaluating ACE inhibitors in aortic regurgitation have yielded inconsistent results, and very few have assessed clinical outcomes.
Does ACE inhibitor or ARB therapy reduce all-cause mortality and cardiovascular events in patients with at least moderate aortic regurgitation?
Population
2,266 subjects with at least moderate AR in Tayside, Scotland
Comparison
Treatment with vs without ACE inhibitors or ARBs
Design
Retrospective database-linkage cohort study
Follow-up
Mean 4.4 ± 3.7 years
Authors
Loading...
In patients with moderate to severe aortic regurgitation, prescription of ACE inhibitors or ARBs was associated with significantly reduced all-cause mortality and cardiovascular events.
Cohort (n=2,266)
Does ACE inhibitor or ARB therapy reduce all-cause mortality and cardiovascular events in patients with at least moderate aortic regurgitation?
Hazard Ratio: 0.56 (95% CI 0.64–0.89)
p-value: p=< 0.01
In patients with moderate to severe aortic regurgitation, prescription of ACE inhibitors or ARBs was associated with significantly reduced all-cause mortality and cardiovascular events.
Elder et al. (2011) conducted a cohort in Aortic regurgitation (n=2,266). ACE inhibitors or ARBs vs. Without ACE inhibitors or ARBs was evaluated on All-cause mortality (HR 0.56, 95% CI 0.64 to 0.89, p=< 0.01). In patients with moderate to severe aortic regurgitation, ACE inhibitor or ARB therapy was associated with reduced all-cause mortality (HR 0.56; 95% CI 0.64-0.89; p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: